Literature DB >> 24135919

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

O Alejandro Balbin1, John R Prensner, Anirban Sahu, Anastasia Yocum, Sunita Shankar, Rohit Malik, Damian Fermin, Saravana M Dhanasekaran, Benjamin Chandler, Dafydd Thomas, David G Beer, Xuhong Cao, Alexey I Nesvizhskii, Arul M Chinnaiyan.   

Abstract

Global 'multi-omics' profiling of cancer cells harbours the potential for characterizing the signalling networks associated with specific oncogenes. Here we profile the transcriptome, proteome and phosphoproteome in a panel of non-small cell lung cancer (NSCLC) cell lines in order to reconstruct targetable networks associated with KRAS dependency. We develop a two-step bioinformatics strategy addressing the challenge of integrating these disparate data sets. We first define an 'abundance-score' combining transcript, protein and phospho-protein abundances to nominate differentially abundant proteins and then use the Prize Collecting Steiner Tree algorithm to identify functional sub-networks. We identify three modules centred on KRAS and MET, LCK and PAK1 and β-Catenin. We validate activation of these proteins in KRAS-dependent (KRAS-Dep) cells and perform functional studies defining LCK as a critical gene for cell proliferation in KRAS-Dep but not KRAS-independent NSCLCs. These results suggest that LCK is a potential druggable target protein in KRAS-Dep lung cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135919      PMCID: PMC4107456          DOI: 10.1038/ncomms3617

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  64 in total

1.  Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis.

Authors:  Sandeep Robert Datta; Ann M Ranger; Michael Z Lin; James Fitzhugh Sturgill; Yong-Chao Ma; Chris W Cowan; Pieter Dikkes; Stanley J Korsmeyer; Michael E Greenberg
Journal:  Dev Cell       Date:  2002-11       Impact factor: 12.270

2.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry.

Authors:  Joshua E Elias; Steven P Gygi
Journal:  Nat Methods       Date:  2007-03       Impact factor: 28.547

3.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.

Authors:  Uma T Shankavaram; William C Reinhold; Satoshi Nishizuka; Sylvia Major; Daisaku Morita; Krishna K Chary; Mark A Reimers; Uwe Scherf; Ari Kahn; Douglas Dolginow; Jeffrey Cossman; Eric P Kaldjian; Dominic A Scudiero; Emanuel Petricoin; Lance Liotta; Jae K Lee; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2007-03-05       Impact factor: 6.261

4.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

Authors:  Andrea H Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Joshi; David Harpole; Johnathan M Lancaster; Andrew Berchuck; John A Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

Review 5.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

6.  Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Authors:  Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn R Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

7.  Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition.

Authors:  Venkateshwar G Keshamouni; Pratik Jagtap; George Michailidis; John R Strahler; Rork Kuick; Ajaya Kumar Reka; Panagiotis Papoulias; Rashmi Krishnapuram; Anjaiah Srirangam; Theodore J Standiford; Philip C Andrews; Gilbert S Omenn
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

8.  TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.

Authors:  Anurag Singh; Michael F Sweeney; Min Yu; Alexa Burger; Patricia Greninger; Cyril Benes; Daniel A Haber; Jeff Settleman
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

9.  The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013.

Authors:  Juan Antonio Vizcaíno; Richard G Côté; Attila Csordas; José A Dianes; Antonio Fabregat; Joseph M Foster; Johannes Griss; Emanuele Alpi; Melih Birim; Javier Contell; Gavin O'Kelly; Andreas Schoenegger; David Ovelleiro; Yasset Pérez-Riverol; Florian Reisinger; Daniel Ríos; Rui Wang; Henning Hermjakob
Journal:  Nucleic Acids Res       Date:  2012-11-29       Impact factor: 16.971

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  29 in total

Review 1.  Rapid learning for precision oncology.

Authors:  Jeff Shrager; Jay M Tenenbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

Review 2.  Targeting PAK1.

Authors:  Galina Semenova; Jonathan Chernoff
Journal:  Biochem Soc Trans       Date:  2017-02-08       Impact factor: 5.407

Review 3.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

4.  KRAS AND THE REALITY OF PERSONALIZED MEDICINE IN NON-SMALL CELL LUNG CANCER.

Authors:  Havva O Kilgoz; Guzide Bender; Joseph M Scandura; Agnes Viale; Bahar Taneri
Journal:  Mol Med       Date:  2016-07-07       Impact factor: 6.354

Review 5.  Update in Lung Cancer 2014.

Authors:  Avrum Spira; Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

Review 6.  Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.

Authors:  Matthias Drosten; Mariano Barbacid
Journal:  J Mol Med (Berl)       Date:  2015-11-03       Impact factor: 4.599

7.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.

Authors:  Erin Sheffels; Nancy E Sealover; Chenyue Wang; Do Hyung Kim; Isabella A Vazirani; Elizabeth Lee; Elizabeth M Terrell; Deborah K Morrison; Ji Luo; Robert L Kortum
Journal:  Sci Signal       Date:  2018-09-04       Impact factor: 8.192

8.  Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.

Authors:  Jianxin Shi; Hongcheng Liu; Feng Yao; Chenxi Zhong; Heng Zhao
Journal:  Tumour Biol       Date:  2014-10-02

Review 9.  The Role of Wild-Type RAS in Oncogenic RAS Transformation.

Authors:  Erin Sheffels; Robert L Kortum
Journal:  Genes (Basel)       Date:  2021-04-28       Impact factor: 4.096

10.  Novel Application of Junction Trees to the Interpretation of Epigenetic Differences among Lung Cancer Subtypes.

Authors:  Arturo Lopez Pineda; Vanathi Gopalakrishnan
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2015-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.